Removing immunomodulatory protein improves symptoms of muscular dystrophy in mice

Removing immunomodulatory protein improves symptoms of muscular dystrophy in mice: "Removing an immunomodulatory protein called osteopontin improves the symptoms of mice with muscular dystrophy by changing the type of macrophages acting on damaged muscle tissue, according to a paper published in The Journal of Cell Biology. The study, "Osteopontin ablation ameliorates muscular dystrophy by shifting macrophages to a pro-regenerative phenotype" by Joana Capote and colleagues, adds support to the idea that osteopontin inhibitors could be used to treat patients with Duchenne muscular dystrophy (DMD).

DMD is a progressive, and ultimately fa"



'via Blog this'

» Summit Reports Positive Interim Data from Phase 1 Testing a New Formulation of SMT C1100 in DMD Patients Action Duchenne

» Summit Reports Positive Interim Data from Phase 1 Testing a New Formulation of SMT C1100 in DMD Patients Action Duchenne: "Today, we announced preliminary interim results from an ongoing Phase 1 trial of a new formulation of SMT C1100. As you’ll see in the release pasted below, we just announced data from the first dose in patients (with up to 3 doses planned) and from healthy volunteers. The data are encouraging and the trial is proceeding to the next dose in patients. This new formulation Phase 1 trial is a separate trial to the Phase 2 PhaseOut DMD trial that we’ve been discussing recently. Some questions that you may have:"



'via Blog this'